Summary
A new report released today by Treatment Action Group (TAG) and Stop TB Partnership found that cumulative funding for tuberculosis (TB) research and development (R&D) in 2023 reached only 24% of the annual $5 billion funding target agreed by countries at the United Nations High-Level Meeting (HLM) on TB in September 2023. Significant acceleration of investment — bolstered by broader democratic support from more diversified sources of funding — is necessary to develop and scale up the tools necessary to end TB as a public health crisis by 2030.
